No Data
No Data
Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) Looks Just Right With A 54% Price Jump
Individual Investors Who Hold 43% of Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) Gained 18%, Insiders Profited as Well
Hoyuan Biotech (688238.SH): Shareholders Shanghai Tan Ying, Shanghai Qiangang, and Shanghai Leyong have collectively reduced their shareholding by 0.9990% in the company.
On September 9th, Gelonghui announced that Hemay Bio (688238.SH) has recently received a notice from shareholders Shanghai Tianying, Shanghai Qiangang, and Shanghai Leyong regarding the expiration of the shareholding reduction plan and equity changes reaching 1%. As of September 6th, 2024, shareholders Shanghai Tianying, Shanghai Qiangang, and Shanghai Leyong have cumulatively reduced the company's shareholding through centralized bidding trading by 6,467,856 shares, holding a total of 45,871,444 shares. The shareholding reduction plan of shareholders Shanghai Tianying, Shanghai Qiangang, and Shanghai Leyong has reached the end of the designated time range, and this shareholding reduction plan has been fully implemented.
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
HiFiBio (688238.SH) released its semi-annual performance results with a net loss of 113 million yuan.
Huayuan Biology (688238.SH) disclosed its semi-annual report for 2024, and the company achieved revenue of 1.13 million during the reporting period...
No Data
No Data